Full text
Earnings transcript
Read the complete earnings call transcript.
TDOC
Teladoc Health, Inc.
$6.4
0.07
(1.03%)
| Exchange: | NYSE |
| Market Cap: | 1.162B |
| Shares Outstanding: | 27.613M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Healthcare Information Services | |||||
| CEO: | Charles Divita | |||||
| Full Time Employees: | 5124 | |||||
| Address: |
| |||||
| Website: | https://www.teladochealth.com |
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2,602,415 | 2,569,574 | 2,529,977 |
| Gross Profit | 1,842,384 | 1,818,304 | 1,758,384 |
| EBITDA | 43,613 | 31,723 | 147,304 |
| Operating Income | -248,553 | -1,020,886 | -262,955 |
| Net Income | -220,368 | -1,001,245 | -200,322 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 4,392,369 | 3,516,524 | 2,858,300 |
| Total Liabilities | 2,066,296 | 2,025,445 | 1,472,594 |
| Total Stockholders Equity | 2,326,073 | 1,491,079 | 1,385,706 |
| Total Debt | 1,592,277 | 1,584,613 | 1,029,129 |
| Cash and Cash Equivalents | 1,123,675 | 1,298,327 | 781,084 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 350,021 | 293,680 | 294,357 |
| Capital Expenditure | -156,348 | -10,790 | -8,893 |
| Free Cash Flow | 193,673 | 282,890 | 285,464 |
| Net Income | -220,368 | -1,001,245 | -200,322 |
| Net Change in Cash | 205,493 | 174,652 | -517,243 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 2,415,252.283 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 2,670,933.549 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 2,540,711.500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 322,002.691 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 356,090.250 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 338,728.979 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 11,543.648 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 13,157.427 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 12,335.507 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 1,237,772.644 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 1,368,804.618 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 1,302,068.199 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 0.070 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 0.070 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 0.070 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 6 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 3 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Growth: Based on income statement data, Teladoc Health has shown consistent revenue increases over recent periods, reflecting robust demand for telehealth services. This aligns with industry trends in the healthcare technology sector, where digital health solutions are gaining traction.
- Solid Liquidity Position: The balance sheet indicates a healthy level of cash and cash equivalents relative to total current liabilities, as evidenced by a favorable current ratio (TTM). This provides financial flexibility to fund operations and innovation.
- Market Leadership in Telehealth: As per the company profile, Teladoc operates in a niche but growing industry within the healthcare sector, positioning it as a key player with a strong brand in virtual care delivery.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates TDOC intrinsic value between $23.85 – $24.40 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about TDOC valuation
Is Teladoc Health, Inc. (TDOC) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Teladoc Health, Inc. (TDOC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is TDOC a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TDOC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is TDOC’s P/E ratio?
You can see TDOC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for TDOC?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is TDOC a good long-term investment?
Whether TDOC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
TDOC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.03
Trading Metrics:
| Open: | 6.39 | Previous Close: | 6.33 | |
| Day Low: | 6.37 | Day High: | 6.46 | |
| Year Low: | 4.4 | Year High: | 9.89 | |
| Price Avg 50: | 7.96 | Price Avg 200: | 6.72 | |
| Volume: | 846553 | Average Volume: | 4.958M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeTDOC full analysis
Welcome to MARKETSNAP’s SWOT analysis for Teladoc Health, the company behind the ticker TDOC. If you’re a long-term investor looking to dive into the telehealth space, you’ve likely come across Teladoc Health, a pioneer in virtual healthcare services. Today, we’re breaking down their strengths, weaknesses, opportunities, and threats to help you gauge whether this stock fits into your wealth-building strategy. I’ll keep things conversational, throw in some insights, and make sure we’re covering what matters most for your portfolio. Let’s…
